Definium Therapeutics Inc. (NASDAQ: DFTX) shares moved higher in after-hours trading on Monday, rising 6.38% to $24.66, following a modest gain in the regular session and continued momentum in psychedelic-focused biotech stocks.
Sector Tailwinds Boost Sentiment
The broader psychedelic drug sector has recently seen strong buying interest after a policy shift signaled potential regulatory easing. Stocks in the space rallied after U.S. President Donald Trump issued an executive order aimed at accelerating the review of psychedelic-based therapies, a move viewed by analysts as reducing regulatory uncertainty.
Definium Therapeutics was among the companies benefiting from the sector-wide momentum, alongside peers that also posted sharp premarket gains earlier in the week.
Inducement Grant Announcement
Separately, Definium Therapeutics announced inducement equity grants …
